(Q33332077)

English

Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 reference

based on heuristic

inferred from title

metastatic colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

George Fountzilas

6

object named as

G Fountzilas

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

author name string

J Janinis

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

P Papakostas

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

G Samelis

3

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

D Skarlos

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

P Papagianopoulos

5

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

publication date

1 February 2000

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

163-167

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Population study of dihydropyrimidine dehydrogenase in cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosa

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008397109048

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008397109048

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33332077&oldid=1612244428"